O

Oncolys Biopharma Inc
TSE:4588

Watchlist Manager
Oncolys Biopharma Inc
TSE:4588
Watchlist
Price: 655 JPY -1.06% Market Closed
Updated: May 20, 2024
Financials Section:
Income Statement Balance Sheet Cash Flow Statement

Balance Sheet

2B
+15%
Assets
Growth Rates:
1 Year
-23%
3 Years
-27%
5 Years
-41%
7 Years
-35%
10 Years
-64%
566.5m
+25%
Liabilities
Growth Rates:
1 Year
+15%
3 Years
-29%
5 Years
+7%
7 Years
+8%
10 Years
-6%
1.5B
+12%
Equity
Growth Rates:
1 Year
-32%
3 Years
-26%
5 Years
-49%
7 Years
-44%
10 Years
-71%

Balance Sheet Decomposition
Oncolys Biopharma Inc

2B
Assets
566.5m
Liabilities
2B
Assets
566.5m
Liabilities
Current Assets 2B
Cash & Short-Term Investments 1.5B
Receivables 101.7m
Other Current Assets 321.3m
Non-Current Assets 84.7m
Long-Term Investments 21m
Other Non-Current Assets 63.7m
Current Liabilities 378.5m
Accrued Liabilities 19.1m
Other Current Liabilities 359.4m
Non-Current Liabilities 188m
Long-Term Debt 179.8m
Other Non-Current Liabilities 8.1m

Balance Sheet
Oncolys Biopharma Inc

Rotate your device to view
Balance Sheet
Currency: JPY
Dec-2014 Dec-2015 Dec-2016 Dec-2017 Dec-2018 Dec-2019 Dec-2020 Dec-2021 Dec-2022 Dec-2023
Assets
Cash & Cash Equivalents
4 728
3 605
2 564
2 868
2 463
3 343
2 068
3 455
1 711
1 533
Cash Equivalents
4 728
3 605
2 564
2 868
2 463
3 343
2 068
3 455
1 711
1 533
Total Receivables
60
24
97
122
110
217
168
377
318
102
Accounts Receivables
7
1
66
89
50
169
71
352
0
0
Other Receivables
54
23
31
33
60
48
97
24
0
0
Inventory
19
16
15
19
11
15
10
12
24
5
Other Current Assets
78
29
70
64
34
252
300
355
555
316
Total Current Assets
4 885
3 674
2 747
3 072
2 618
3 826
2 546
4 198
2 609
1 956
PP&E Net
59
46
0
3
2
12
21
0
0
0
PP&E Gross
59
46
0
3
2
12
21
0
0
0
Accumulated Depreciation
55
71
69
68
69
65
69
68
69
71
Intangible Assets
1
4
0
0
0
1
1
0
0
0
Note Receivable
0
0
0
11
11
0
31
35
0
43
Long-Term Investments
25
248
362
410
769
431
112
21
21
21
Other Long-Term Assets
39
34
32
30
29
110
85
38
21
21
Total Assets
5 009
N/A
4 006
-20%
3 140
-22%
3 526
+12%
3 430
-3%
4 380
+28%
2 796
-36%
4 292
+53%
2 651
-38%
2 041
-23%
Liabilities
Accrued Liabilities
19
14
12
11
12
88
15
17
17
19
Short-Term Debt
140
60
60
0
50
50
50
50
50
0
Current Portion of Long-Term Debt
43
44
13
103
39
81
102
192
181
135
Other Current Liabilities
61
59
120
125
111
305
248
172
73
224
Total Current Liabilities
263
177
205
239
212
524
415
430
322
379
Long-Term Debt
366
325
315
352
312
397
373
262
162
180
Deferred Income Tax
6
0
0
0
0
0
0
0
0
0
Other Liabilities
3
3
3
4
4
5
5
6
8
8
Total Liabilities
637
N/A
504
-21%
523
+4%
594
+14%
529
-11%
926
+75%
793
-14%
698
-12%
492
-30%
567
+15%
Equity
Common Stock
5 072
5 072
5 091
5 802
6 403
7 121
7 437
9 040
3 000
3 623
Retained Earnings
5 776
6 630
7 549
8 650
9 884
10 798
12 894
14 509
1 427
3 359
Additional Paid In Capital
5 065
5 065
5 083
5 795
6 395
7 123
7 461
9 064
586
1 210
Unrealized Security Profit/Loss
11
5
8
16
13
8
0
0
0
0
Treasury Stock
0
0
0
0
0
0
0
0
0
0
Other Equity
0
0
0
0
0
0
0
0
0
0
Total Equity
4 372
N/A
3 501
-20%
2 617
-25%
2 932
+12%
2 901
-1%
3 454
+19%
2 003
-42%
3 594
+79%
2 159
-40%
1 474
-32%
Total Liabilities & Equity
5 009
N/A
4 006
-20%
3 140
-22%
3 526
+12%
3 430
-3%
4 380
+28%
2 796
-36%
4 292
+53%
2 651
-38%
2 041
-23%
Shares Outstanding
Common Shares Outstanding
9
9
9
11
13
14
15
17
17
20

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
ALPHA SPREAD
Join more than 138,800+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.